OCCHIO! IPMN (INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS) DEL PANCREAS SI ASSOCIANO A NEOPLASIE EXTRA-PANCREATICHE NEL 27%.UNA META-ANALISI

ECOGRAFIA ED ECOENDOSCOPIA, PANCREAS E VIE BILIARI, REAL WORLD EVIDENCE, Senza categoriaLascia un commento

Association between pancreatic intraductal papillary mucinous neoplasms and extrapancreatic malignancies: A systematic review with meta-analysis Antonio Facciorusso et al. Abstract Background It is unclear whether patients with intraductal papillary mucinous neoplasia harbor a higher risk of developing extrapancreatic malignancies. Aims We performed a pooled estimate of the incidence of extrapancreatic malignancies in patients with intraductal…

RIFAXIMINA E SIMVASTATINA RIDUCONO IL PROFILO METABOLOMICO INFIAMMATORIO DEL CIRROTICO SCOMPENSATO. DAL PROGETTTO LIVERHOPE (FREE)

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, Senza categoriaLascia un commento

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis Elisa Pose et al. ABSTRACT Patients with decompensated cirrhosis, particularly those with acute-on-chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma…

RIFAXIMINA RIDUCE LA INFIAMMAZIONE DI PROVENIENZA INTESTINALE ! IL TRIAL “RIFSYS” SUL J. OF HEPATOLOGY (FREE).

CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, Senza categoriaLascia un commento

Rifaximin-a reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial Vishal C. Patel et al. Highlights   Rifaximin reduced gut-derived systemic inflammation by suppressing oralisation of the gut microbiome.   Rifaximin suppressed mucin-degrading species rich in sialidase, e.g. Streptococcus and Veillonella spp.   Rifaximin promotes an intestinal environment augmenting re-…

OCCHIO! DA GENNAIO 2022 ESCE UN PERICOLOSO CONCORRENTE!

GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, METODOLOGIALascia un commento

  Introducing NEJM Evidence Launching January 2022, NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making. The volume of clinical research continues to grow, yet the standards to establish and validate claims, especially as related to clinical practice, have not followed…

IL GRAVE PROBLEMA DELLA RIPRODUCIBILITA’ (2): PERCHE’ LA RIFORMA SULLA RIPRODUCIBILITA’ STA FALLENDO. DA “NATURE” (FREE)

METODOLOGIA, REAL WORLD EVIDENCELascia un commento

Understand the real reasons reproducibility reform fails Lack of rigour is often blamed on pressure to publish. But ethnographers can find out what truly keeps science from upping its game. Nicole C. Nelson A decade ago, the US National Institute of Neurological Disorders and Stroke convened a workshop on how to improve the rigour of…

COVID-19 ED INCERTEZZA: ASPIRINA FORSE NO!

COVID19 - EVIDENCE, MEDICI DI FAMIGLIA, MEDICINA INTERNA, METODOLOGIA, Senza categoriaLascia un commento

Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19 Husam M. Salah, et al. Repurposing of existing medications has widely been used in studies since the emergence of coronavirus disease 2019 (COVID-19). Besides dexamethasone in selected patients, no medical treatment to date has been shown to improve mortality in patients with COVID-19 infection. Aspirin…